Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS. https://lnkd.in/gNwiGnJy
Vasomune Therapeutics, Inc.
Pharmaceutical Manufacturing
Toronto, Ontario 1,522 followers
Biopharmaceutical leaders developing the next generation of medicine to normalize host vascular response
About us
Vasomune Therapeutics is a private biotechnology company developing the next generation of medicine. Our innovative approach focuses on combating vascular dysfunction and defending against illness by activating the Tie2 pathway Our company’s lead drug candidate targets a signaling molecule responsible for regulating the vascular response to injury (vascular leak) which is associated with a wide range of diseases such as Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury, sepsis and Cardiopulmonary Bypass. Through pioneering the fight against vascular leak and by decreasing the activity of multiple proinflammatory factors, we can greatly increase the chances of patient health and success. For more, visit www.vasomune.com
- Website
-
http://www.vasomune.com
External link for Vasomune Therapeutics, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Biotechnology, Pharmaceutical, Life Sciences, Health Science, and Business
Locations
-
Primary
180 John St
Suite 305
Toronto, Ontario M5T 1X5, CA
-
223 S West St
#900
Raleigh, North Carolina 27603, US
Employees at Vasomune Therapeutics, Inc.
Updates
-
Congratulations Dr Harold Kim
Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium (MHSRS)! The MHSRS is the Department of Defense premier military/civilian meeting that focuses specifically on the unique medical needs of the Warfighter. We are grateful to the US Department of Defense CDMRP for all their support. Thanks to the Peer Reviewed Medical Research Program (PRMRP), whose goal is to enhance the health, care, and well-being of military Service members, Veterans, retirees, and their families. With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS. Keep moving forward!! #2024MHSRS
-
-
Thank you ARDS Alliance and Paula Blonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important.
Today we celebrate World ARDS Awareness Day! What will you do today to increase awareness? Join us in helping ALL those affected by ARDS. #ardsalliance #ards #joinus
-
Vasomune Therapeutics, Inc. is proud to share that Dr. Harold Kim, Vice-President Research and Scientific Affairs, will present poster MHSRS-24-11804, entitled: “A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-dose Pharmacokinetic First in Human Study of AV-001 in Healthy Subjects for the Treatment of Acute Respiratory Distress Syndrome,” at 2024 Military Health System Research Symposium. MHSRS, the United States’ foremost annual military-healthcare conference, is scheduled from 26-29 August 2024 at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. The highly selective event, hosted by the U.S. Department of Defense, is the primary scientific meeting for warfighter healthcare concerns, including medical countermeasures and critical care treatment. Vasomune is grateful to the United States Department of Defense Congressionally Directed Medical Research Programs award #PR191212 for support to advance AV-001 to the clinic and award #PR203503 for support to research AV-001 in Phase 2a. Vasomune is also grateful to the National Research Council Canada / Conseil national de recherches Canada Industrial Research Assistance Program for providing research and development funding which supported the Phase 1 study. #Vasomune https://www.mhsrs.net/
2024 Military Health System Research Symposium (MHSRS)
mhsrs.net
-
Fascinating research and promising results for Vasomune's AV-001 to treat Vascular Dementia, "...the second most frequent subtype of dementia after Alzheimer’s disease, accounting for about 20% of dementia cases in North America." From the publication: AV-001 treatment alleviates neurological deficits and long-term memory impairment AV-001 treatment improves WM (white matter) integrity and promotes axonal/WM remodeling AV-001 significantly decreases the expression of cytokines in CSF (cerebrospinal fluid)
Vascular endothelial dysfunction is a key driver of so many devastating diseases. Congratulations to the team of Dr. Michael Chopp at Henry Ford Hospital, particularly Dr. Huanjia Gao, for a fascinating look at how AV-001 might be used in the treatment of vascular dementia. Thanks to Dr. Harold Kim for supporting this fruitful collaboration. https://lnkd.in/gsTUWyVA #Vasomune #dementia
Frontiers | Publisher of peer-reviewed articles in open access journals
frontiersin.org
-
Vascular endothelial dysfunction is a key driver of so many devastating diseases. Congratulations to the team of Dr. Michael Chopp at Henry Ford Hospital, particularly Dr. Huanjia Gao, for a fascinating look at how AV-001 might be used in the treatment of vascular dementia. Thanks to Dr. Harold Kim for supporting this fruitful collaboration. https://lnkd.in/gsTUWyVA #Vasomune #dementia
Frontiers | Publisher of peer-reviewed articles in open access journals
frontiersin.org
-
Vasomune Therapeutics, Inc. reposted this
It was our honour to host this opening #marsimpacthealth start-up pitch session, and introduce an amazing group of #entrepreneurs and new health #innovations from Vasomune Therapeutics, Inc., Ripple Therapeutics , QurCan Therapeutics Inc., NorthMiRs, Modulari-T Bio, Canurta Therapeutics and Intrepid Labs to the community.... Many thanks to MaRS Discovery District for the opportunity and to everyone who joined the session!
-
-
Vasomune Therapeutics, Inc. reposted this
Join Dr. Brian Jahns for a presentation of Vasomune Therapeutics, Inc., MaRS Discovery District Impact Health Conference, June 12 and 13. https://lnkd.in/g-ZtCSy
Program - MaRS Impact Health
impacthealth.marsdd.com
-
Join Dr. Brian Jahns for a presentation of Vasomune Therapeutics, Inc., MaRS Discovery District Impact Health Conference, June 12 and 13. https://lnkd.in/g-ZtCSy
Program - MaRS Impact Health
impacthealth.marsdd.com
-
Vasomune Therapeutics, Inc. reposted this
Commercialization | Development | Strategy | BD&L | Corporate Director | Medical Countermeasures | I/O | Pharma Investor
On Monday June 5 at 3pm PST I present the Vasomune Therapeutics story. Join me in Theater 3 for the story of how we achieved the ATS Late Breaker and Fast Track Designation, and what our vision is, for the future. https://lnkd.in/gBj3A9mu
Vasomune Therapeutics Inc
convention.bio.org